대한예방한의학회지 (Journal of Society of Preventive Korean Medicine)

대한예방한의학회 (Society of Preventive Korean Medicine)
권호 표지

일엽추 추출물이 RANKL 유도 RAW264.7 Cell의 유전자 발현에 미치는 영향

Effects of Securinega suffructicosa(SS) Extract on Osteoclastogenesis and Gene Expression in RANKL-induced RAW Cell

  • 이효근 (경원대학교 한의과대학 예방의학교실) ;
  • 황귀서 (경원대학교 한의과대학 예방의학교실)
  • Lee, Hyo-Keun (Department of Preventive Medicine, College of Oriental Medicine, Kyungwon University) ;
  • Hwang, Gwi-Seo (Department of Preventive Medicine, College of Oriental Medicine, Kyungwon University)
  • 투고 : 2010.12.06
  • 심사 : 2010.12.23
  • 발행 : 2010.12.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Objectives : This study was performed to evaluate the effect of Securinega suffructicosa Rehder (SS) on osteoclast differentiation and gene expression. Methods : The osteoclastogenesis and gene expression were determined in RANKL-stimulated RAW 264.7. The results were summarized as followes. Results : SS decreased the number of TRAP positive cell in RANKL-stimulated RAW264.7 cell. SS decreased the expression of RANK, TNF${\alpha}$, and IL-6 in RANKL-stimulated RAW264.7 cell. SS decreased the expression of iNOS and COX-2 in RANKL-stimulated RAW264.7 cell. SS decreased the expression of Cathepsin K in RANKL-stimulated RAW264.7 cell. Conclusions : It is concluded that SS might decrease the bone resorption resulted from decrease of osteoclast differentiation and it's related gene expression.

키워드

참고문헌

  1. E. Canalis. Mechanisms of Glucocorticoid action in Bone : Implications to glucocorticoidinduced osteoporosis, J. Clion. Endocri. Met. 1996 ; 81 : 3441-3447. https://doi.org/10.1210/jc.81.10.3441
  2. Pietschmann P, Rauner M, Sipos W, Kerschan-Schindl K. Osteoporosis : an agerelated and gender-specific disease. Gerontology. 2008 ; 55(1) : 3-12.
  3. Pacifici R. Estrogen deficiency, T cells and bone loss. Cell Immunol. 2008 ; 252 (1-2) : 68-80. https://doi.org/10.1016/j.cellimm.2007.06.008
  4. Kumamoto H, Ooya K. Expression of parathyroid hormone-related protein (PTHrP), osteoclast differentiation factor (ODF)/receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoclastogenesis inhibitory factor (OCIF)/osteoprotegerin (OPG) in ameloblastomas. J Oral Pathol Med. 2004 ; 33(1): 46-52. https://doi.org/10.1111/j.1600-0714.2004.00204.x
  5. Reddy SV. Regulatory mechanisms operative in osteoclasts. Crit Rev Eukaryot Gene Expr. 2004 ; 14(4) : 255-70. https://doi.org/10.1615/CritRevEukaryotGeneExpr.v14.i4.20
  6. Boyce BF, Yamashita T, Yao Z, Zhang Q, Li F, Xing L. Roles for NF-kappaB and c-Fos in osteoclasts. J Bone Miner Metab. 2005 ; 23 Suppl : 11-5. https://doi.org/10.1007/BF03026317
  7. Murakami A, Song M, Ohigashi H. Phenethyl isothiocyanate suppresses receptor activator of NF-kappaB ligand (RANKL)- induced osteoclastogenesis by blocking activation of ERK1/2 and p38 MAPK in RAW- 264.7 macrophages. Biofactors. 2007 ; 30(1) : 1-11. https://doi.org/10.1002/biof.5520300101
  8. Pang M, Martinez AF, Fernandez I, Balkan W, Troen BR. AP-1 stimulates the cathepsin K promoter in RAW 264.7 cells. Gene. 2007 ; 403(1-2) : 151-8. https://doi.org/10.1016/j.gene.2007.08.007
  9. Lee ZH, Kim HH. Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts. Biochem Biophys Res Commun. 2003 ; 305(2) : 211-4. https://doi.org/10.1016/S0006-291X(03)00695-8
  10. Lee SC, Lee KS, Roh JS, Park WY, Lee SH, Ahn BT, Chemical Study on the Phenolic Compounds from the Leaves of Securinega suffruticosa. Kor J Pharmacog. 1994; 25(2):105-112.
  11. Ohsaki A, Kobayashi Y, Yoneda K, Kishida A, Ishiyama H. Securinega alkaloids from the wood of Securinega suffruticosa var. amamiensis. J Nat Prod. 2007 ; 70 (12) : 2003-5. https://doi.org/10.1021/np0780102
  12. Lee SC, Ahn BT, Lee KS. Chemical study on the phenolic compounds from the leaves of Securinega suffruticosa. Kor J Pharmacog. 1994 ; 25 : 105.
  13. Raj D, Luczkiewicz M. Securinega suffruticosa. Fitoterapia. 2008 ; 79(6) : 419-27. https://doi.org/10.1016/j.fitote.2008.02.011
  14. Beutler JA, Karbon EW, and Brubaker AN. Securinine alkaloids : A new class of GABA receptor antagonist. Brain Res. 1985 ; 330 : 135-140. https://doi.org/10.1016/0006-8993(85)90014-9
  15. Jang CH, Eun JS, Park HW, Seo SM, Yang JH, Leem KH, Oh SH, Kim DK. An Acetylcholinesterase Inhibitor from the Leaves of Securinega suffruticosa. Kor J Pharmacog. 2003 ; 34(1) : 14-17
  16. Meiyanto E, Hoshijima M, Ogawa T, Ishida N, Takeya T. Osteoclast differentiation factor modulates cell cycle machinery and causes a delay in s phase progression in RAW264 cells. Biochem Biophys Res Commun. 2001 ; 282(1) : 278-83. https://doi.org/10.1006/bbrc.2001.4564
  17. John T. Swarthout, Richard C. D'Alonzob, Nagarajan Selvamurugan and Nicola C. Partridge. Parathyroid hormone-dependent signaling pathways regulating genes in bone cells. Gene 2002 ; 282(1-2) : 1-17. https://doi.org/10.1016/S0378-1119(01)00798-3
  18. Cho ES, Yu JH, Kim MS, Yim M. Rolipram, a phosphodiesterase 4 inhibitor, stimulates osteoclast formation by inducing TRANCE expression in mouse calvarial cells. Arch Pharm Res. 2004 ; 27(12) : 1258-62. https://doi.org/10.1007/BF02975891
  19. Khosla S. Minireview : the OPG/RANKL/ RANK system. Endocrinology. 2001 ; 142 (12) : 5050-5. https://doi.org/10.1210/en.142.12.5050
  20. Gallea S, Lallemand F, Atfi A, Rawadi G, Ramez V, Spinella-Jaegle S, Kawai S, Faucheu C, Huet L, Baron R, Roman- Roman S. Activation of mitogen-activated protein kinase cascades is involved in regulation of bone morphogenetic protein- 2-induced osteoblast differentiation in pluripotent C2C12 cells. Bone. 2001 ; 28(5) : 491-8. https://doi.org/10.1016/S8756-3282(01)00415-X
  21. Yao Z, Li P, Zhang Q, Schwarz EM, Keng P, Arbini A, Boyce BF, Xing L. Tumor necrosis factor-alpha increases circulating osteoclast precursor numbers by promoting their proliferation and differentiation in the bone marrow through up-regulation of c- Fms expression. J Biol Chem. 2006 ; 281 (17) : 11846-55. https://doi.org/10.1074/jbc.M512624200
  22. Liu XH, Kirschenbaum A, Yao S, Levine AC. Interactive effect of interleukin-6 and prostaglandin E2 on osteoclastogenesis via the OPG/RANKL/RANK system. Ann N Y Acad Sci. 2006 ; 1068 : 225-33. https://doi.org/10.1196/annals.1346.047
  23. Han SY, Lee NK, Kim KH, Jang IW, Yim M, Kim JH, Lee WJ, Lee SY. Transcriptional induction of cyclooxygenase-2 in osteoclast precursors is involved in RANKL-induced osteoclastogenesis. Blood. 2005 ; 106(4) : 1240-5. https://doi.org/10.1182/blood-2004-12-4975
  24. Wei X, Zhang X, Zuscik MJ, Drissi MH, Schwarz EM, O'Keefe RJ. Fibroblasts express RANKL and support osteoclastogenesis in a COX-2-dependent manner after stimulation with titanium particles. J Bone Miner Res. 2005 ; 20(7) : 1136-48. https://doi.org/10.1359/JBMR.050206
  25. Fukushima H, Jimi E, Kajiya H, Motokawa W, Okabe K. Parathyroid-hormone-related protein induces expression of receptor activator of NF-{kappa}B ligand in human periodontal ligament cells via a cAMP/ protein kinase A-independent pathway. J Dent Res. 2005 ; 84(4) : 329-34. https://doi.org/10.1177/154405910508400407
  26. 34. Lin TH, Yang RS, Tang CH, Lin CP, Fu WM. PPARgamma inhibits osteogenesis via the down-regulation of the expression of COX-2 and iNOS in rats. Bone. 2007 Oct ; 41(4) : 562-74. https://doi.org/10.1016/j.bone.2007.06.017
  27. Zheng H, Yu X, Collin-Osdoby P, Osdoby P. RANKL stimulates inducible nitric-oxide synthase expression and nitric oxide production in developing osteoclasts. An autocrine negative feedback mechanism triggered by RANKL-induced interferon-beta via NF-kappaB that restrains osteoclastogenesis and bone resorption. J Biol Chem. 2006 ; 281(23) : 15809-20. https://doi.org/10.1074/jbc.M513225200